Table 1 Characteristics of study population of opioid agonist treatment (OAT) patients in the Czech Republic and Norway during 2010–2019
|  | Czech Republic (N = 4,280) | Norway (N = 11,389) | ||
|---|---|---|---|---|
| Â | Men | Women | Men | Women |
Number of OAT patients (n, %) | 2992 (69.9) | 1288 (30.1) | 8006 (70.3) | 3383 (29.7) |
Age at 2015 | Â | Â | Â | Â |
Mean (SD) | 35.8 (6.6) | 33 (6.5) | 42.8 (10.2) | 41.8 (10.4) |
First OAT medication | Â | Â | Â | Â |
Methadone (n, %) | 946 (31.6) | 446 (34.6) | 2557 (31.9) | 1142 (33.8) |
Buprenorphine (n, %) | 1225 (40.9) | 512 (39.8) | 2723 (34.0) | 1215 (35.9) |
Buprenorphine-naloxone (n, %) | 821 (27.4) | 330 (25.6) | 2726 (34.0) | 1036 (30.3) |